Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DYSMENORRHEA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DYSMENORRHEA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
5.3 COMPETITIVE INTELLIGENCE
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 CLINICAL TRIALS FOR DYSMENORRHEA TREATMENT MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE: DYSMENORRHEA TREATMENT MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE: DYSMENORRHEA TREATMENT MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE DYSMENORRHEA TREATMENT MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR DYSMENORRHEA TREATMENT MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDIACTION
11.3 PHARACOLOGICAL CLASS OD THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 PACKAGING TYPE
11.1 DRUG ROUTE OF ADMINISTRATION
11.11 DOSING FREQUENCY
11.12 DRUG INSIGHT
11.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.13.1 FORECAST MARKET OUTLOOK
11.13.2 CROSS COMPETITION
11.13.3 THERAPEUTIC PORTFOLIO
11.13.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE
15.1 OVERVIEW
15.1.1 PRIMARY DYSMENORRHEA
15.1.2 SECONDARY DYSMENORRHEA
15.1.2.1. ENDOMETRIOSIS-RELATED DYSMENORRHEA
15.1.2.2. UTERINE FIBROIDS-RELATED DYSMENORRHEA
15.1.2.3. PELVIC INFLAMMATORY DISEASE (PID) DYSMENORRHEA
15.1.2.4. ADENOMYOSIS-RELATED DYSMENORRHEA
15.1.2.5. CERVICAL STENOSIS-RELATED DYSMENORRHEA
15.1.2.6. OTHERS
16 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TREATMENT TYPE
16.1 OVERVIEW
16.2 PAIN RELIEVERS
16.2.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
16.2.1.1. IBUPROFEN
16.2.1.2. NAPROXEN
16.2.1.3. MEFENAMIC ACID
16.2.1.4. DICLOFENAC
16.2.1.5. ASPIRIN
16.2.2 ANALGESICS & MUSCLE RELAXANTS
16.2.2.1. ACETAMINOPHEN
16.2.2.2. OPIOIDS
16.2.2.3. CODEINE
16.2.2.4. TRAMADOL
16.2.2.5. OXYCODONE
16.2.2.6. OTHERS
16.2.3 CYCLOBENZAPRINE & BACLOFEN
16.2.4 OTHERS
16.3 HORMONAL THERAPY
16.3.1 COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC)
16.3.1.1. NORGESTIMATE/ETHINYL ESTRADIOL
16.3.1.2. NORETHINDRONE/ETHINYL ESTRADIOL
16.3.2 EXTENDED-CYCLE ORAL CONTRACEPTIVES
16.3.2.1. LEVONORGESTREL/ETHINYL ESTRADIOL
16.3.2.2. LEVONORGESTREL/ETHINYL ESTRADIOL
16.3.2.3. OTHER
16.3.3 ETONOGESTREL IMPLANT
16.3.4 ETONOGESTREL/ETHINYL ESTRADIOL
16.3.5 LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM
16.3.6 MEDROXYPROGESTERONE SHOT
16.4 SURGICAL TREATMENT
16.4.1 MINIMALLY INVASIVE SURGERIES
16.4.1.1. LAPAROSCOPIC SURGERY (FOR ENDOMETRIOSIS, FIBROIDS)
16.4.1.2. HYSTEROSCOPY (FOR UTERINE ABNORMALITIES)
16.4.2 MAJOR SURGICAL PROCEDURES
16.4.2.1. HYSTERECTOMY (UTERUS REMOVAL)
16.4.2.2. MYOMECTOMY (FIBROID REMOVAL)
16.4.2.3. ENDOMETRIAL ABLATION
16.4.2.4. OTHER
16.5 OTHER THERAPY
16.5.1 HEAT THERAPY
16.5.1.1. PATCH
16.5.1.2. WRAP
16.5.1.3. CERAMIC BELT EMITTING FAR-INFRARED RADIATION (FIR)
16.5.2 BEHAVIORAL COUNSELING
16.5.2.1. DESENSITIZATION-BASED PROCEDURES
16.5.2.2. HYPNOTHERAPY
16.5.2.3. IMAGERY
16.5.2.4. COPING STRATEGIES
16.5.2.5. OTHERS
16.5.3 DIET AND VITAMINS
16.5.3.1. VITAMIN E
16.5.3.2. VITAMIN B
16.5.3.3. VITAMIN D
16.5.3.4. OTHERS
16.6 OTHERS
17 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
17.1 OVERVIEW
17.2 ORAL
17.3 PARENTERAL
17.4 TOPICAL
17.5 OTHERS
18 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY DRUG TYPE
18.1 OVERVIEW
18.2 BRANDED
18.3 GENERIC
19 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY MODE OF PURCHASE
19.1 OVERVIEW
19.2 PRESCRIPTION BASED
19.3 OVER THE COUNTER
20 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.3 AMUBALATORY SURGICAL CENTERS
20.4 SPECIALTY CLINICS
20.5 RESEARCH & ACADEMIC INSTITUTES
20.6 HOME HEALTHCARE
20.7 OTHERS
21 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 ONLINE
21.3.2 OFFLINE
21.4 OTHERS
22 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY GEOGRAPHY
22.1 GLOBAL DYSMENORRHEA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.2 NORTH AMERICA
22.2.1 U.S.
22.2.2 CANADA
22.2.3 MEXICO
22.3 EUROPE
22.3.1 GERMANY
22.3.2 FRANCE
22.3.3 U.K.
22.3.4 ITALY
22.3.5 SPAIN
22.3.6 RUSSIA
22.3.7 TURKEY
22.3.8 BELGIUM
22.3.9 NETHERLANDS
22.3.10 SWITZERLAND
22.3.11 REST OF EUROPE
22.4 ASIA PACIFIC
22.4.1 JAPAN
22.4.2 CHINA
22.4.3 SOUTH KOREA
22.4.4 INDIA
22.4.5 AUSTRALIA
22.4.6 SINGAPORE
22.4.7 THAILAND
22.4.8 MALAYSIA
22.4.9 INDONESIA
22.4.10 PHILIPPINES
22.4.11 REST OF ASIA PACIFIC
22.5 SOUTH AMERICA
22.5.1 BRAZIL
22.5.2 ARGENTINA
22.5.3 REST OF SOUTH AMERICA
22.6 MIDDLE EAST AND AFRICA
22.6.1 SOUTH AFRICA
22.6.2 EGYPT
22.6.3 SAUDI ARABIA
22.6.4 U.A.E
22.6.5 ISRAEL
22.6.6 REST OF MIDDLE EAST AND AFRICA
22.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL DYSMENORRHEA TREATMENT MARKET,COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT AND APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL DYSMENORRHEA TREATMENT MARKET , SWOT & DBMR ANALYSIS
25 GLOBAL DYSMENORRHEA TREATMENT MARKET, COMPANY PROFILE
25.1 GLAXOSMITHKLINE PLC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 CUMBERLAND PHARMACEUTICALS INC
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 BAYER AG
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 PFIZER INC.
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 MYLAN N.V.
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 ALVOGEN
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 MERCK & CO., INC
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 TEVA PHARMACEUTICAL INDUSTRIES LTD.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 BOEHRINGER INGELHEIM
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 LUPIN
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 SANOFI
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 COMFORTÉ
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 BIOELECTRONICS CORPORATION
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 ABBVIE INC.
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 NOBELPHARMA AMERICA, LLC.
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 MYOVANT SCIENCES GMBH
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 NOVARTIS AG
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 AMERICAN REGENT, INC. (A SUBSIDIARY OF DAIICHI SANKYO GROUP COMPANY)
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 OBSEVA
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
25.21 NEUROCRINE BIOSCIENCES
25.21.1 COMPANY OVERVIEW
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPMENTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
